Pharmaceutical Preparations
Standard Industrial Classification: SIC 2834
Industry Insider Sentiment Analysis
The Pharmaceutical Preparations sector (SIC 2834) acts as a critical barometer for broader economic health. Our real-time monitoring reveals total transactions. Monitoring "cluster buying" is one of the most reliable leading indicators for future sector performance. By analyzing aggregate data across this specific Standard Industrial Classification, investors can filter out individual company volatility and identify high-conviction trends. When multiple directors and officers within the same industry move capital simultaneously, it often signals an upcoming sector-wide revaluation or a fundamental shift in supply chain dynamics that has yet to be recognized by the broader public market.
| Filing Date | Trade Date | Ticker | Company | Reporting Person | Relationship | Type | Price | Qty | Total, $ | Owned After |
|---|---|---|---|---|---|---|---|---|---|---|
| 2026-05-15 01:08 | 2026-05-01 | LGND | LIGAND PHARMACEUTICALS INC | KOZARICH JOHN W | Director | OPT+S | $225.14 | 2,501 | $563,080 | 41,786 |
| 2026-05-15 00:05 | 2026-05-12 | STTK | Shattuck Labs, Inc. | Shukla Abhinav A. | Officer | OPT+S | $7.01 | 2,032 | $14,244 | 81,258 |
| 2026-05-15 00:00 | 2026-05-12 | STTK | Shattuck Labs, Inc. | Pandite Arundathy N. | Officer | SELL | $6.61 | 30,000 | $198,300 | 166,219 |
| 2026-05-14 23:05 | 2026-05-12 | ARWR | ARROWHEAD PHARMACEUTICALS, INC. | Lu Hongbo | Director | SELL | $76.88 | 2,970 | $228,334 | 52,012 |
| 2026-05-14 21:54 | 2026-05-13 | UTHR | UNITED THERAPEUTICS Corp | ROTHBLATT MARTINE A | Director, Officer | OPT+S | $578.65 | 9,500 | $5,497,166 | 40,513 |
| 2026-05-14 20:22 | 2026-05-13 | RCKT | ROCKET PHARMACEUTICALS, INC. | Wilson Martin | Officer | SELL | $3.61 | 3,361 | $12,120 | 678,639 |
| 2026-05-14 20:26 | 2026-05-14 | CYTK | CYTOKINETICS INC | Blum Robert I | Director, Officer | SELL | $77.92 | 7,500 | $584,400 | 400,330 |
| 2026-05-14 20:16 | - | ZOMDF | Zomedica Corp. | POWERS JOHNNY D | Director | BUY | $0.11 | 300,000 | $31,710 | 4,225,000 |
| 2026-05-14 20:16 | 2026-05-13 | RCKT | ROCKET PHARMACEUTICALS, INC. | Militello John | Officer | SELL | $3.61 | 855 | $3,083 | 90,164 |
| 2026-05-14 20:19 | 2026-05-13 | RCKT | ROCKET PHARMACEUTICALS, INC. | Shah Gaurav | Officer | SELL | $3.61 | 2,728 | $9,837 | 1,043,327 |
| 2026-05-14 20:02 | 2026-05-13 | DYN | Dyne Therapeutics, Inc. | Cox John | Director, Officer | SELL | $18.36 | 3,311 | $60,790 | 370,834 |
| 2026-05-14 20:03 | 2026-05-13 | DYN | Dyne Therapeutics, Inc. | Lucera Erick | Officer | SELL | $18.36 | 1,448 | $26,585 | 123,925 |
| 2026-05-14 20:04 | 2026-05-13 | DYN | Dyne Therapeutics, Inc. | Kerr Douglas | Officer | SELL | $18.36 | 1,564 | $28,715 | 170,042 |
| 2026-05-13 20:26 | 2026-05-12 | VERA | Vera Therapeutics, Inc. | Fordyce Marshall | Director, Officer | SELL | $36.74 | 18,500 | $679,747 | 216,744 |
| 2026-05-13 20:10 | 2026-05-11 | MLTX | MoonLake Immunotherapeutics | Bodenstedt Matthias | Officer | SELL | $20.02 | 13,653 | $273,333 | 1,172,431 |
| 2026-05-13 20:18 | 2026-05-11 | ARVN | ARVINAS, INC. | Saik Andrew | Officer | SELL | $9.94 | 11,139 | $110,693 | 193,128 |
| 2026-05-13 20:25 | 2026-05-12 | KALV | KalVista Pharmaceuticals, Inc. | Palleiko Benjamin L | Director, Officer | OPT+S | $26.71 | 3,322 | $88,731 | 466,375 |
| 2026-05-13 20:05 | 2026-05-11 | COLL | COLLEGIUM PHARMACEUTICAL, INC | BOHLIN GAREN G | Director | OPT+S | $37.18 | 8,700 | $323,491 | 62,259 |
| 2026-05-13 20:06 | 2026-05-13 | HOWL | Werewolf Therapeutics, Inc. | EVNIN LUKE | Director | SELL | $0.54 | 44,679 | $24,127 | 1,126,496 |
| 2026-05-14 01:42 | 2026-05-11 | MLYS | Mineralys Therapeutics, Inc. | Rodman David Malcom | Officer | OPT+S | $28.91 | 22,575 | $652,639 | 63,443 |
| 2026-05-14 01:22 | 2026-05-11 | RLYB | Rallybio Corp | ADAR1 Capital Management, LLC | 10% owner | BUY | $14.00 | 50,800 | $711,053 | 830,584 |
| 2026-05-14 00:22 | 2026-05-11 | ANIP | ANI PHARMACEUTICALS INC | Walsh Patrick D | Director | SELL | $80.66 | 13,973 | $1,127,119 | 38,432 |
| 2026-05-14 00:30 | 2026-05-12 | MNKD | MANNKIND CORP | Thomson David | Officer | SELL | $3.29 | 3,033 | $9,979 | 826,299 |
| 2026-05-14 00:30 | 2026-05-12 | MNKD | MANNKIND CORP | Binder Steven B. | Director | SELL | $3.29 | 16,940 | $55,733 | 808,008 |
| 2026-05-14 00:00 | 2026-05-11 | JANX | Janux Therapeutics, Inc. | Dobek Maria | Officer | SELL | $14.17 | 2,038 | $28,878 | 32,270 |
| 2026-05-13 23:42 | 2026-05-11 | ARQT | Arcutis Biotherapeutics, Inc. | Burnett Patrick | Officer | SELL | $21.05 | 222 | $4,673 | 120,244 |
| 2026-05-13 23:43 | 2026-05-11 | ARQT | Arcutis Biotherapeutics, Inc. | Vairavan Latha | Officer | SELL | $21.05 | 435 | $9,157 | 85,978 |
| 2026-05-13 23:06 | 2026-05-11 | RAPP | Rapport Therapeutics, Inc. | Third Rock Ventures V, L.P. | 10% owner | SELL | $40.24 | 133,618 | $5,377,323 | 6,299,097 |
| 2026-05-13 22:04 | 2026-05-11 | CLNN | Clene Inc. | Ugwumba Chidozie | 10% owner | SELL | $6.33 | 95,473 | $604,134 | 103,417 |
| 2026-05-13 20:50 | 2026-05-11 | INSM | INSMED Inc | Flammer Martina M.D. | Officer | OPT+S | $100.40 | 12,949 | $1,300,121 | 83,243 |
| 2026-05-13 20:35 | 2026-05-13 | ZTS | Zoetis Inc. | Bisaro Paul | Director | BUY | $75.88 | 2,000 | $151,750 | 27,862 |
| 2026-05-13 20:35 | 2026-05-13 | ZTS | Zoetis Inc. | DAMELIO FRANK A | Director | BUY | $75.39 | 6,650 | $501,344 | 21,458 |
| 2026-05-13 20:30 | 2026-05-11 | ANNX | Annexon, Inc. | Carson William H. | Director | BUY | $5.78 | 8,000 | $46,240 | 78,405 |
| 2026-05-13 20:30 | 2026-05-11 | LQDA | Liquidia Corp | Bloch Stephen M | Director | SELL | $50.23 | 318,893 | $16,016,784 | 1,870,042 |
| 2026-05-13 20:31 | 2026-05-12 | UTHR | UNITED THERAPEUTICS Corp | Mesa Nilda | Director | SELL | $581.94 | 258 | $150,139 | 5,028 |
| 2026-05-13 20:31 | 2026-05-11 | VRDN | Viridian Therapeutics, Inc.\DE | Fairmount Funds Management LLC | Director, 10% owner | BUY | $17.00 | 1,176,470 | $19,999,990 | 5,090,928 |
| 2026-05-13 20:31 | 2026-05-12 | UTHR | UNITED THERAPEUTICS Corp | ROTHBLATT MARTINE A | Director, Officer | OPT+S | $578.38 | 9,500 | $5,494,563 | 40,513 |
| 2026-05-13 20:32 | 2026-05-11 | ZVRA | ZEVRA THERAPEUTICS, INC. | Thompson Rahsaan | Officer | SELL | $11.30 | 1,794 | $20,272 | 48,125 |
| 2026-05-13 20:15 | 2026-05-11 | ARVN | ARVINAS, INC. | Teel Randy | Director, Officer | SELL | $9.94 | 9,657 | $95,965 | 287,218 |
| 2026-05-13 20:15 | 2026-05-13 | ANIP | ANI PHARMACEUTICALS INC | Cook Meredith | Officer | SELL | $78.16 | 500 | $39,080 | 78,390 |
| 2026-05-13 20:15 | 2026-05-12 | ANIP | ANI PHARMACEUTICALS INC | Gutwerg Ori | Officer | SELL | $79.50 | 2,772 | $220,374 | 78,696 |
| 2026-05-13 20:16 | 2026-05-11 | ARVN | ARVINAS, INC. | Berkowitz Noah | Officer | SELL | $9.94 | 11,108 | $110,385 | 191,395 |
| 2026-05-13 20:16 | 2026-05-11 | ANIP | ANI PHARMACEUTICALS INC | Lalwani Nikhil | Director, Officer | SELL | $77.57 | 55,000 | $4,266,350 | 349,889 |
| 2026-05-13 20:16 | 2026-05-12 | ANIP | ANI PHARMACEUTICALS INC | Rowland Thomas Andrew | Officer | SELL | $79.21 | 459 | $36,357 | 38,271 |
| 2026-05-13 20:16 | 2026-05-11 | ARVN | ARVINAS, INC. | Cacace Angela M | Officer | SELL | $9.94 | 9,657 | $95,965 | 182,966 |
| 2026-05-13 20:17 | 2026-05-11 | ARVN | ARVINAS, INC. | Loomis David K | Officer | SELL | $9.94 | 1,919 | $19,070 | 40,193 |
| 2026-05-13 12:47 | 2026-04-30 | RNTX | Rein Therapeutics, Inc. | WINDSOR JAMES BRIAN | Director, Officer | BUY | $1.00 | 25,000 | $25,000 | 27,046 |
| 2026-05-12 20:10 | 2026-05-11 | AMRX | Amneal Pharmaceuticals, Inc. | Autor Deborah M. | Director | SELL | $12.94 | 34,819 | $450,558 | 93,660 |
| 2026-05-12 20:09 | 2026-05-11 | RCUS | Arcus Biosciences, Inc. | Goeltz II Robert C. | Officer | SELL | $25.63 | 7,763 | $198,966 | 84,161 |
| 2026-05-12 20:08 | 2026-05-11 | ASND | Ascendis Pharma A/S | JENSEN FLEMMING STEEN | Officer | SELL | $238.49 | 19,460 | $4,641,021 | 0 |
Sector-Wide Insider Alpha
Analyzing insider movements across the Pharmaceutical Preparations sector provides a macro-view of executive conviction. When multiple leaders in different companies within the same SIC code (2834) simultaneously buy shares, it often indicates an industry-wide undervaluation or a positive shift in market cycles.
SEC Filings in Pharmaceutical Preparations
Every transaction in the Pharmaceutical Preparations industry is reported via Form 4 disclosures. By filtering these filings by industry, investors can detect institutional-scale sentiment shifts before they are reflected in broader market indices, following the capital flow of those with intimate industry knowledge.
UNDERSTANDING THE DATA
FILING DATE: The date and time when the transaction was reported to the SEC. This is when the public first receives the information.
TRADE DATE: The actual day the insider executed the purchase or sale in the market.
INDUSTRY: The specific market sector the company operates in. Useful for identifying broader institutional capital flows across sectors.
OWNED AFTER: The total number of shares held by the insider following the transaction. This highlights the insider's remaining conviction in the company.
CHANGE %: The percentage increase or decrease of the insider's total position. Large percentage changes often carry more weight than the dollar amount alone.
TRADE TYPES DEFINITIONS
BUY: An open market purchase. Typically indicates an insider's belief that the stock is undervalued or poised for growth.
SELL: An open market sale. While often used for diversification or liquidity, large or unexpected sales can be a warning signal.
OPT+S (OPTION EXERCISE & SALE): This occurs when an insider exercises their stock options and sells them immediately. Often part of a structured compensation plan.